Prostate Cancer Clinical Trial

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Summary

This Phase 2 study will investigate the safety and clinical activity of XmAb20717 alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have been treated with at least 2 prior lines of anticancer therapy.

View Full Description

Full Description

Detailed Description:

This is a Phase 2, open-label, multiple-dose, multiple-arm, parallel assignment study in patients with mCRPC who have progressed on prior therapy. It will enroll subjects into 1 of 5 molecularly defined cohorts based on the results of acceptable, documented prior diagnostic testing:

Cohort A: Aggressive variant prostate cancer (AVPCa)
Cohort B: Homologous recombination deficient (HRD)/cyclin-dependent kinase 12 (CDK12) biallelic loss tumors that have progressed on poly-adenosine diphosphate ribose polymerase inhibitors (HRD/CDK12 PARP Progressors) - Closed to Enrollment
Cohort C: HRD/CDK12 biallelic loss tumors, naive to PARP inhibitors (HRD/CDK12 PARP Naïve) - Closed to Enrollment
Cohort D: Microsatellite instability-high (MSI-H) or mismatch repair deficient (MMRD), or tumor mutational burden-high (TMB-H) tumors - Closed to Enrollment
Cohort E: No Targetable Mutations

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Able to provide written informed consent
Adult (age ≥ 18 years)
Histologically confirmed diagnosis of carcinoma of the prostate

Documented progressive mCRPC based on at least one of the following criteria:

PSA progression, defined as at least 2 rises in PSA with a minimum of a 1-week interval (1.0 ng/mL is the minimal starting value if confirmed rise is the only indication of progression)
Soft-tissue progression per RECIST 1.1
Progression of bone disease (evaluable disease) or 2 or more new bone lesions by bone scan
Progression after prior therapy
Subjects who did not have a surgical orchiectomy must be on androgen suppression treatment (eg, luteinizing hormone-releasing hormone agonist) with castrate level of testosterone (≤ 50 ng/dL) and be willing to continue the treatment throughout the study

Prior targeted or whole exome sequencing panel performed by CLIA-certified laboratory documenting:

Cohort A (AVPCa) - Aggressive variant prostate cancer
Cohort B or C (HRD) - Homologous recombination deficient (HRD) tumor
Cohort D (MSI-H/MMRD) - Microsatellite instability-high (MSI-H) or mismatch repair deficient (MMRD) tumors (MSI-H/MMRD) or TMB-H (≥ 10 mut/Mb)
Cohort E (No Targetable Mutations)

NOTE: Cohorts B, C, and D are no longer open for enrollment

Evaluable disease according to PCWG3 criteria
Adequate archival metastatic tumor tissue or agree to undergo a biopsy of at least 1 metastatic site (fresh biopsy of primary prostate is only allowed if there is clear local disease and no other measurable disease site or biopsiable bone lesion)
ECOG performance status of 0 or 1
Able and willing to complete the study according to the study schedule

Exclusion Criteria:

Currently receiving anticancer therapies other than androgen deprivation therapy
Prior treatment with docetaxel (Cohort E only)
Treatment with any other anticancer therapy within 2 weeks of the start of study drug (ie, other immunotherapy, chemotherapy, radiation therapy, etc.)
Disease progression on prior treatment with cabazitaxel plus carboplatin (applicable to subjects eligible for Cohort A) or cabazitaxel alone (applicable to subjects eligible for Cohorts B and E)
Prior treatment with any cytotoxic T-lymphocyte-associated protein (CTLA4), PD1, PDL1, or programmed cell death ligand 2 (PDL2) directed immunotherapy, except subjects in Cohort D, who will have had prior FDA-approved checkpoint inhibitor therapy
Grade 4 immune-mediated adverse events related to prior immunotherapy (applicable to subjects eligible for Cohort D)
Failure to recover from any toxicity related to previous anticancer treatment to ≤ Grade 2
Have known active central nervous system metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable, ie, are without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), are clinically stable, and are without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
Platelet count < 100 × 109/L
Hemoglobin level ≤ 9.0 g/dL
Absolute neutrophil count ≤ 1.7 × 109 for subjects who will receive cabazitaxel; < 1.0 × 109/L for all others
Aspartate aminotransferase at screening > 3 × upper limit of normal (ULN) for subjects without known liver involvement by tumor or > 5 × ULN for subjects with known liver involvement by tumor
Alanine aminotransferase at screening > 3 × ULN for subjects without known liver involvement by tumor or > 5 × ULN for subjects with known liver involvement by tumor
Bilirubin ≥ 1.5 × ULN (unless prior diagnosis and documentation of ongoing hemolysis or Gilbert's syndrome has been made)
Estimated creatinine clearance < 50 mL/minute calculated by the Cockcroft Gault or Modification of Diet in Renal Disease formulas
Active known or suspected autoimmune disease (except vitiligo; type 1 diabetes mellitus or residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and nonsteroidal anti-inflammatory drugs)
Have any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug (except inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response). Subjects who are currently taking prednisone from a previous prostate cancer therapy will be permitted to enroll in the study.
Receipt of an organ allograft
Known history of left ventricular ejection fraction ≤ 40%
History or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease other than their primary malignancy that, in the opinion of the Investigator, would pose a risk to patient safety or interfere with study evaluations, procedures, or completion
Evidence of any serious bacterial, viral, parasitic, or systemic fungal infections within the 30 days prior to the first dose of study drug
Receipt of a live-virus vaccine within 30 days prior to the first dose of study drug (seasonal flu vaccines that do not contain live virus are permitted)
Known human immunodeficiency virus (HIV) positive subject with CD4+ T-cell (CD4+) counts < 350 cells/μL, or an HIV viral load greater than 400 copies/mL, or a history of an AIDS (acquired immunodeficiency syndrome)-defining opportunistic infection within the past 12 months, or who has not been on established antiretroviral therapy (ART) for at least 4 weeks prior to initiation of study drug dosing. (Effective ART is defined as a drug, dosage, and schedule associated with reduction and control of the viral load.) (HIV positive subjects who do not meet any of these exclusion criteria are eligible)
Positive test for hepatitis C RNA (a subject who is hepatitis C virus [HCV] antibody positive but HCV RNA negative due to documented, curative prior antiviral treatment or natural resolution is eligible)
Positive test for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb; a subject whose HBsAg is negative and HBcAb is positive may be enrolled if a hepatitis B virus [HBV] DNA test is negative and the subject is retested for HBsAg and HBV DNA every 2 months)

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

85

Study ID:

NCT05005728

Recruitment Status:

Recruiting

Sponsor:

Xencor, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 17 Locations for this study

See Locations Near You

Mayo Clinic Hospital
Phoenix Arizona, 85054, United States
City of Hope
Duarte California, 91010, United States
VA Greater Los Angeles
Los Angeles California, 90064, United States
University of California, San Diego
San Diego California, 92093, United States
Mayo Clinic
Jacksonville Florida, 32224, United States
The University of Chicago Medical Center
Chicago Illinois, 60637, United States
University of Iowa Hospitals & Clinics
Iowa City Iowa, 52242, United States
University of Kansas Clinical Research Center
Fairway Kansas, 66205, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
GU Research Network/Urology Cancer Center
Omaha Nebraska, 68130, United States
Comprehensive Cancer Centers of Nevada
Las Vegas Nevada, 89148, United States
XCancer New Mexico Oncology Hematology Consultants, Ltd.
Albuquerque New Mexico, 87109, United States
Montefiore Medical Center
Bronx New York, 10461, United States
Columbia University
New York New York, 10032, United States
University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States
UPMC Hillman Cancer Center
Pittsburgh Pennsylvania, 15232, United States
University of Washington/Seattle Cancer Care/Alliance
Seattle Washington, 98109, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

85

Study ID:

NCT05005728

Recruitment Status:

Recruiting

Sponsor:


Xencor, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.